Sakita I, Hörig H, Sun R, Wang F, Nathenson S G
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
J Immunol Methods. 1996 Jun 10;192(1-2):105-15. doi: 10.1016/0022-1759(96)00027-0.
The use of peptides as a vaccine is a potentially powerful immunization strategy. We explored the possibility of inducing an efficient cytotoxic T lymphocyte (CTL) mediated immune response in mice, using in vitro reconstituted major histocompatibility complex (MHC) class I/peptide complexes as the immunogen. Recombinant derived H-2Kb and beta 2-microglobulin (beta 2m) were properly folded into an MHC class I complex using the vesicular stomatitis virus (VSV)-8mer from the natural nucleocapsid proteinN52-59 (RGYVYQGL), an immunodominant Kb epitope in C57BL/6 (B6) mice. After immunizing mice with the H-2Kb class I/VSV peptide complex and a subsequent in vitro stimulation with the VSV peptide alone, a specific CTL response was demonstrated. The method was also applicable to other peptides, for example, the Sendai virus (SV) peptideN324-332 (FAPGNYPAL). The CTL response was mediated by CD3+/CD8+ T cells and was shown to be allele specific, as only peptide loaded target cells expressing the H-2Kb allele could be recognized. It is of interest that extremely small amounts of injected MHC class I/peptide complex (i.e. 500 pg) could generate a measurable CTL response. The MHC class I/peptide complex had to be intact and properly folded to elicit an immune response, suggesting that the complex protected the peptide for internalization by antigen presenting cells (APCs) or for delivering to the proper site for peptide exchange on the cell surface of APCs. The described immunizing method can be routinely used to prime a CTL response by employing in vitro folded MHC class I/peptide complexes, without the use of adjuvants. It appears to be efficient, sensitive and specific. By using the recombinant protein system, unlimited amounts of MHC class I/peptide complex can be produced for immunization. Moreover, this protocol permits different in vitro combinations of allelic MHC class I molecules and peptide variants.
将肽用作疫苗是一种具有潜在强大作用的免疫策略。我们利用体外重组的主要组织相容性复合体(MHC)I类/肽复合物作为免疫原,探讨了在小鼠中诱导高效细胞毒性T淋巴细胞(CTL)介导的免疫反应的可能性。使用来自天然核衣壳蛋白N52 - 59(RGYVYQGL)的水疱性口炎病毒(VSV)- 8聚体,将重组衍生的H - 2Kb和β2 - 微球蛋白(β2m)正确折叠成MHC I类复合物,该8聚体是C57BL / 6(B6)小鼠中的免疫显性Kb表位。在用H - 2Kb I类/VSV肽复合物免疫小鼠并随后仅用VSV肽进行体外刺激后,证明了特异性CTL反应。该方法也适用于其他肽,例如仙台病毒(SV)肽N324 - 332(FAPGNYPAL)。CTL反应由CD3 + /CD8 + T细胞介导,并且显示为等位基因特异性,因为只有表达H - 2Kb等位基因的肽负载靶细胞才能被识别。有趣的是,极少量注射的MHC I类/肽复合物(即500 pg)就能产生可测量的CTL反应。MHC I类/肽复合物必须完整且正确折叠才能引发免疫反应,这表明该复合物保护肽以便被抗原呈递细胞(APC)内化或递送至APC细胞表面进行肽交换的合适位点。所描述的免疫方法可常规用于通过使用体外折叠的MHC I类/肽复合物引发CTL反应,而无需使用佐剂。它似乎是高效、灵敏和特异的。通过使用重组蛋白系统,可以生产无限量的MHC I类/肽复合物用于免疫。此外,该方案允许等位基因MHC I类分子和肽变体的不同体外组合。